AL Amyloidosis – Epidemiology Forecast—2030

AL Amyloidosis – Epidemiology Forecast—2030

  • December 2020 •
  • 89 pages •
  • Report ID: 5993615 •
  • Format: PDF
‘AL Amyloidosis – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

AL Amyloidosis Disease Understanding
Amyloidosis refers to a group of complex diseases caused by protein misfolding and aggregation into highly ordered amyloid fibrils that deposit in tissues, resulting in progressive organ damage. A cross-?-sheet quaternary structure characterizes these amyloid fibrils. It is typically found in individuals with monoclonal gammopathy.
AL amyloidosis is characterized by the proliferation of clonal plasma cells. It causes the increased production of immunoglobulin light chains to become misfolded and aggregate into amyloid fibrils, leading to organ damage. As the amyloid builds up in an organ, nerve, or tissue, it gradually causes damage and affects their function. Each amyloidosis patient has a different pattern of amyloid deposition in their body. It often affects more than one organ, except the brain.

AL Amyloidosis Epidemiology
The AL amyloidosis epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the Incident patient pool and their trends along with assumptions undertaken.

Key Findings
The total Incident cases of AL Amyloidosis patients in the 7MM will rise during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical and forecasted AL amyloidosis symptoms epidemiology segmented as the total incident cases of AL amyloidosis, Gender-specific cases of AL amyloidosis, and age-specific cases of AL amyloidosis. The report presents the incident scenario of AL amyloidosis symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country-wise Epidemiology of AL Amyloidosis
The epidemiology segment also provides the AL Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total Incident cases of AL Amyloidosis associated in 7MM countries were 8,550 in 2017.
• As per the estimates, the United States has the largest incident population of AL amyloidosis.
• In 2017, among the EU5 countries, Germany had the highest Incident cases of AL amyloidosis, followed by France. On the other hand, Spain had the lowest Incident cases, with 406 cases.

Scope of the Report
• The AL amyloidosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The AL amyloidosis Epidemiology Report and Model provide an overview of the risk factors and global trends of AL Amyloidosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted AL amyloidosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of AL amyloidosis.
• The report provides the AL amyloidosis epidemiology segmentation by incident cases of AL amyloidosis in the 7MM.
• The report provides the AL amyloidosis epidemiology segmentation by gender-specific incident cases of AL amyloidosis in the 7MM.
• The report provides the AL amyloidosis epidemiology segmentation by age-specific incident Cases of AL Amyloidosis in the 7MM.

Report Highlights

• 11-year Forecast of AL Amyloidosis epidemiology
• 7MM Coverage
• Total Incident Cases of AL amyloidosis
• Incident Cases according to segmentation: Gender-specific cases of AL Amyloidosis
• Incident Cases according to segmentation: Age-specific cases of AL Amyloidosis

KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM for the patient population of AL amyloidosis?
• What are the key findings of the AL amyloidosis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of AL amyloidosis patients across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the AL Amyloidosis?
• What are the currently available treatments of AL Amyloidosis?

Reasons to buy
The AL Amyloidosis epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global AL Amyloidosis market
• Quantify patient populations in the global AL Amyloidosis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AL Amyloidosis therapeutics in each of the markets covered
• Understand the magnitude of AL amyloidosis population by its incident cases
• Understand the magnitude of AL amyloidosis population by its gender-specific cases
• Understand the magnitude of AL amyloidosis population by its age-specific cases
• The AL amyloidosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The AL amyloidosis Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
The unique, comprehensive medical data source available for the population of Olmsted County, Minnesota, has been of great value in determining incidence trends and prevalence rates for various diseases. Given the paucity of epidemiologic studies in AL amyloidosis, the data from the Olmsted, the country was compared throughout 1950–1989.
Kyle et al. (1992.) determined the incidence and natural history of primary systemic amyloidosis. The data from the records of all residents of Olmsted County were used, wherein a diagnosis of amyloidosis was obtained from the Mayo Clinic and its affiliated hospitals and other medical groups that might have seen local patients for the period January 1950 to December 1989. A total of 21 patients fulfilled the criteria for the diagnosis of AL; the median age was 73.5 years; 62% were men. Congestive heart failure was present in 33%, nephrotic syndrome, macroglossia 19%, carpal tunnel syndrome, hepatomegaly, renal failure (10%), and orthostatic hypotension, intermittent claudication, cardiac arrhythmia, pseudo-obstruction of the small bowel, and marked weight loss. The rectal biopsy was positive in 67%, and a bone marrow biopsy was positive in 42%. The median duration of survival from diagnosis was 2.3 years.
The age-adjusted rates were significantly greater in men than women. The age- and sex-adjusted rates were 3.9, 7.6, 5.9, and 14.4 per million person-years for the four decades from 1950 through 1989. The age-specific incidence rates increased in each decade of life after age 40 years in both men and women, except for a non-significant decrease after the eighth decade in women. No patients were younger than 40 years. The age-wise data was reported as 3.0 7.6, 15.4, 64.6, 113 for 40–49, 50–59, 60–69, 70–79, and more than 80. The overall sex- and age-adjusted rate per million person-years was 6.1 from 1950 to 1969 and 10.5 from 1970 to 1989. The similarity of these rates suggests no significant increase over time. It is the most comprehensive epidemiological study to date, and the overall age- and sex-adjusted annual rate per million person-years was 8.9 for the general population.